• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 3. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 4. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 5. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Professional Introduction to Boc-N-Methyl-DL-Leucine (CAS No. 13734-32-2)

Boc-N-Methyl-DL-Leucine, with the chemical compound identifier CAS No. 13734-32-2, is a vital intermediate in the field of pharmaceutical synthesis and peptidomimetics. This compound, characterized by its Boc (tert-butoxycarbonyl) protecting group and N-methylation, plays a crucial role in the development of novel bioactive molecules.

The Boc group in Boc-N-Methyl-DL-Leucine serves as an effective protecting agent for the amine functionality, ensuring selective reactivity in multi-step synthetic pathways. This protection is essential for maintaining the structural integrity of peptides and peptidomimetics during complex chemical modifications. The N-methylation enhances the steric hindrance and stability of the resulting molecules, making them more resistant to enzymatic degradation and improving their pharmacokinetic properties.

In recent years, Boc-N-Methyl-DL-Leucine has garnered significant attention in the design of peptidomimetics aimed at modulating biological pathways. Peptidomimetics are synthetic analogs of natural peptides that mimic their bioactivity while offering improved pharmacological profiles. The incorporation of N-methylated residues into these mimics often leads to enhanced binding affinity and selectivity, which are critical for therapeutic applications.

One of the most compelling applications of Boc-N-Methyl-DL-Leucine is in the development of protease inhibitors. Proteases are enzymes that play a pivotal role in various physiological processes, including inflammation, blood clotting, and viral replication. By designing peptidomimetics that specifically inhibit target proteases, researchers can develop novel therapeutics with high precision. For instance, N-methylated peptidomimetics have shown promise in inhibiting matrix metalloproteinases (MMPs), which are implicated in conditions such as cancer metastasis and rheumatoid arthritis.

The synthesis of complex peptidomimetics often requires a series of well-planned chemical transformations. The use of Boc-N-Methyl-DL-Leucine as a building block allows for efficient assembly of these molecules through solid-phase peptide synthesis (SPPS) or solution-phase methodologies. The Boc protection group ensures that the amine functionality remains inert until the desired point in the synthesis, while the N-methylation provides stability throughout the process.

Recent advancements in computational chemistry have further enhanced the utility of Boc-N-Methyl-DL-Leucine. Molecular modeling techniques enable researchers to predict the binding modes and interactions of peptidomimetics with their target proteins. This computational approach has been instrumental in optimizing lead compounds for drug discovery pipelines. By leveraging these tools, scientists can design more effective peptidomimetics with improved solubility, bioavailability, and metabolic stability.

The pharmaceutical industry has also explored the use of Boc-N-Methyl-DL-Leucine in the development of vaccine adjuvants. Peptide-based vaccines require adjuvants to enhance immune responses. N-methylated peptides have been shown to exhibit adjuvant properties by stimulating innate immune cells and promoting cytokine release. This application has opened new avenues for developing more potent and effective vaccine formulations.

In conclusion, Boc-N-Methyl-DL-Leucine (CAS No. 13734-32-2) is a versatile building block with significant implications in pharmaceutical research and development. Its unique structural features make it an invaluable tool for synthesizing peptidomimetics with enhanced stability and bioactivity. As research continues to uncover new applications for this compound, its importance in drug discovery is likely to grow even further.

• 2419-94-5(N-Boc-L-glutamic acid)
• 53308-95-5(Boc-Nva-OH)
• 13139-16-7(Boc-L-Ile-OH)
• 13726-69-7(Boc-Hyp-OH)
• 15761-39-4(Boc-L-Pro-OH)
• 16937-99-8((tert-Butoxycarbonyl)-D-leucine)
• 13139-15-6(Boc-L-Leu-OH)
• 70491-05-3(Boc-D-Chg-OH)
• 21887-64-9(Nα-Boc-L-Ornithine)
• 13734-28-6(Boc-Lys-OH)